Ad
related to: cleopatra trial breast cancer
Search results
Results from the WOW.Com Content Network
In 2012, the results were published of the CLEOPATRA trial, a randomized placebo-controlled Phase III trial of pertuzumab in combination with trastuzumab and docetaxel in HER2-positive metastatic breast cancer. [21] Pertuzumab received US FDA approval for the treatment of HER2-positive metastatic breast cancer later that year. [8]
The Alliance seeks to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer. The Alliance conducts trials in the following disease and modality areas: breast ...
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.
A Black mom, 33, found a gumball sized lump in her breast. She had stage 3 triple negative cancer. A clinical trial saved her life. Now she educates other Black women.
Jamie LaScala was diagnosed with Stage 3 breast cancer when her son was 6 years old. She responded well to treatment and has been cancer-free since, but like many patients, she worries about her ...
Fisher's impact on breast-cancer treatment was the subject of an August 2013 article in the Atlantic Monthly that was occasioned by his 95th birthday. "Before 1971, if you had breast cancer, chances are you'd have to get your breast cut off", the article recalled. "Surgeons had been taught one thing: radical surgery saves lives.
(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low ...
By conducting a meta-analysis of four large breast cancer trials including nearly 3,000 patients, the researchers have discovered that an abnormality on chromosome 17, called CEP17, is associated with a worse outcome for patients, but also that its presence is a highly significant indicator that the tumor will respond to anthracyclines. [12]
Ad
related to: cleopatra trial breast cancer